Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 9;9(10):3233.
doi: 10.3390/jcm9103233.

Treatment with Intravenous Methylprednisolone in Patients with Graves' Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate

Affiliations

Treatment with Intravenous Methylprednisolone in Patients with Graves' Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate

Katarzyna Pelewicz et al. J Clin Med. .

Abstract

Treatment of active, moderate-to-severe Graves' orbitopathy (GO) is the administration of intravenous methylprednisolone (IVMP). IVMP may be followed by additional therapy with oral prednisone. The aim of this study was to analyze the impact of IVMP on adrenal function by evaluation of serum, salivary cortisol and serum dehydroepiandrosterone sulfate (DHEA-S). Fourteen patients received IVMP treatment (cumulative dose of 4.5 g in 12 weekly infusions) followed by oral prednisone (for three months). All patients showed normal adrenal function before the 12th IVMP pulse and one patient was diagnosed with secondary adrenal insufficiency (AI) after prednisone treatment. DHEA-S was significantly lower before the 12th IVMP pulse and after oral prednisone (p = 0.015 and p = 0.00002, respectively) in comparison to evaluation before therapy. DHEA-S levels were below the reference range in one and three patients before the 12th IVMP pulse and after prednisone therapy, respectively. We observed decreased serum (p = 0.05) and salivary (p = 0.011) cortisol levels after oral prednisone therapy in comparison to evaluation before therapy. Treatment with IVMP in a cumulative dose of 4.5 g affects adrenal function, causing more severe impairment of DHEA-S secretion than that of cortisol but does not cause secondary AI. Additional therapy with oral glucocorticoids after IVMP can cause secondary AI.

Keywords: Graves’ ophthalmopathy; Graves’ orbitopathy; adrenal insufficiency; dehydroepiandrosterone sulfate; glucocorticoids; methylprednisolone; salivary cortisol; serum cortisol.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Comparison of variables during intravenous methylprednisolone treatment. (A) and (B) show cortisol levels in serum and saliva, respectively; (C) shows serum DHEA-S levels; (D) shows plasma ACTH levels. Abbreviations: ACTH, adrenocorticotropic hormone; DHEA-S, dehydroepiandrosterone sulfate; normal ranges: serum cortisol 6.2–19.4 µg/dL; salivary cortisol 0.11–1.29 µg/dL; ACTH 7.2–63.6 pg/mL; serum DHEA-S age and sex-adjusted reference ranges were used.

References

    1. Bartalena L., Baldeschi L., Boboridis K., Eckstein A., Kahaly G.J., Marcocci C., Perros P., Salvi M., Wiersinga W.M. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur. Thyroid J. 2016;5:9–26. doi: 10.1159/000443828. - DOI - PMC - PubMed
    1. Bartalena L., Baldeschi L., Dickinson A., Eckstein A., Kendall-Taylor P., Marcocci C., Mourits M., Perros P., Boboridis K., Boschi A., et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur. J. Endocrinol. 2008;158:273–285. doi: 10.1530/EJE-07-0666. - DOI - PubMed
    1. Miśkiewicz P., Kryczka A., Ambroziak U., Rutkowska B., Główczyńska R., Opolski G., Kahaly G., Bednarczuk T. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves’ orbitopathy safe? Endokrynol. Pol. 2014;65:402–413. doi: 10.5603/EP.2014.0056. - DOI - PubMed
    1. Bornstein S.R., Allolio B., Arlt W., Barthel A., Don-wauchope A., Hammer G.D., Husebye E.S., Merke D.P., Murad H., Stratakis C.A., et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2016;101:364–389. doi: 10.1210/jc.2015-1710. - DOI - PMC - PubMed
    1. Mendel C.M., Kuhn R.W., Weisiger R.A., Cavalieri R.R., Siiteri P.K., Cunha G.R., Murai J.T. Uptake of cortisol by the perfused rat liver: Validity of the free hormone hypothesis applied to cortisol. Endocrinology. 1989;124:468–476. doi: 10.1210/endo-124-1-468. - DOI - PubMed

LinkOut - more resources